Severity
Low
FDA Drug recall · Reported December 26, 2018
Failed Impurities/Degradation Specifications:Out of specification for impurities.
VistaPharm, Inc. recalled NYSTATIN Oral Suspension, USP 500,000 Units/5mL, unit dose 5ml cups, packaged in a) 50 un… - a low-severity action.
NYSTATIN Oral Suspension, USP 500,000 Units/5mL, unit dose 5ml cups, packaged in a) 50 un… was recalled by VistaPharm, Inc. in December 26, 2018. Reason: Failed Impurities/Degradation Specifications:Out of specification for impurities.. Check the official notice for the remedy. Verify recall #D-0348-2019 with the FDA Drug before acting.
The recall
VistaPharm, Inc. issued this low-severity FDA Drug recall-Failed Impurities/Degradation Specifications:Out of specification for impurities..
Sourced from official FDA Drug enforcement records. Verify recall #D-0348-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0348-2019) was formally reported on December 26, 2018, with the manufacturer initiating the action on November 30, 2018. It is classified under Low severity (Class III), with a current status of Terminated. VistaPharm, Inc. is listed as the recalling firm, operating out of Largo, FL. Federal records list the affected scope as 4,065,550 5 ml cups.
The documented reason for this recall is: Failed Impurities/Degradation Specifications:Out of specification for impurities. Distribution data in the federal record shows the product reached: Nationwide in the USA and Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
4,065,550 5 ml cups
Related Recalls
6
5 from same agency
NYSTATIN Oral Suspension, USP 500,000 Units/5mL, unit dose 5ml cups, packaged in a) 50 unit dose cups (10x5ml unit dose cups per tray, 5 trays per case) NDC 66689-037-50; b) 100 unit dose cups (10x5ml unit dose cups per tray, 10 trays per case) NDC 66689-037-99. Rx Only, Manufactured by VistaPharm, Inc. Largo, FL 33771
Failed Impurities/Degradation Specifications:Out of specification for impurities.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0348-2019 |
| Date reported | December 26, 2018 |
| Date initiated | November 30, 2018 |
| Recalling firm | VistaPharm, Inc. |
| Firm location | Largo, FL |
| Affected scope | 4,065,550 5 ml cups |
| Distribution | Nationwide in the USA and Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported December 26, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.